1225 Potential long-term cost savings due to significant clinical benefit of pertuzumab in combination with trastuzumab for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer
2015
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI